ScreenerHero

NBTX Nanobiotix S.A.

NAS · US · Healthcare · Biotechnology · nanobiotix.com
24.62USD-2.42%Mkt Cap: 1.25B $P/E: —

Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD
HeadlineSourceTime
Older
Can J&J’s Partnership Drive More Upside for Nanobiotix?

Guggenheim has assumed coverage of Nanobiotix S.A. (NASDAQ:NBTX) with a Buy rating and a $64 price target on September 15, putting the company’s Johnson & Johnson-partnered JNJ-1900 at the center of its investment thesis. The analyst’s attention is particularly focused on NANORAY-312, the pivotal Phase 3 study evaluating JNJ-1900 in patients with locally advanced head […]

Insider Monkey
Nanobiotix (NBTX): Can Lung Tumor Control Justify Repeat Radiation Risks?

Nanobiotix S.A. (NASDAQ:NBTX) reported September 14 results from all 24 patients in the dose-escalation and expansion portions of a Phase 1 study of JNJ-1900, also called NBTXR3, combined with repeat radiation. The study enrolled patients with inoperable, locoregionally recurrent non-small cell lung cancer. Nanobiotix S.A. (NASDAQ:NBTX) reported 79% one-year locoregional control at a median follow-up […]

Insider Monkey